HealthDay News — For older adults, low-dose aspirin does not reduce the risk for depression, according to a study published online June 3 in JAMA Psychiatry.

Michael Berk, M.B.B.Ch., Ph.D., from the Deakin University School of Medicine in Geelong, Australia, and colleagues conducted a double-blind trial to determine the impact of low-dose aspirin (100 mg) on the risk for depression among healthy older adults. Participants included individuals of all races/ethnicities older than 70 years in Australia and white individuals older than 70 years and black and Hispanic individuals older than 65 years in the United States. A total of 19,114 participants were enrolled: 9,525 and 9,589 received aspirin and placebo, respectively, and were followed for a median of 4.7 years.

The researchers found that the proportion of Center for Epidemiologic Studies Depression 10-item (CES-D-10) scale scores of 8 or higher did not differ significantly at annual visits in the aspirin and placebo groups. The incidence rate of new CES-D-10 scores of 8 or higher was 70.4 and 69.1 events per 1,000 person-years in the aspirin and placebo groups, respectively (hazard ratio, 1.02; 95 percent confidence interval, 0.96 to 1.08; P = 0.54).

“This study failed to confirm any potential benefit of low-dose aspirin in reducing the risk of depression in this relatively healthy older population,” the authors write.


Continue Reading

Several authors disclosed financial ties to the biopharmaceutical and nutrition industries.

Abstract/Full Text (subscription or payment may be required)